Why Is Intel Struggling Against AMD?
Due to its disappointing reports, so-so management, and lack of…
Sell
21
INGN Quote, Financials, Valuation and Earnings
Last price:
$6.88
Seasonality move
:
6.37%
Day range:
$6.69 - $6.90
52-week range:
$6.40 - $13.33
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.47x
P/B ratio:
1.03x
Volume:
187.4K
Avg. volume:
333.8K
1-year change:
0.45%
Market cap:
$178.5M
Revenue:
$335.7M
EPS (TTM):
-$1.52
Analysts' Opinion
-
Consensus RatingInogen has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $10.00, Inogen has an estimated upside of 48.59% from its current price of $6.73.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $10.00 representing 100% downside risk from its current price of $6.73.
Fair Value
-
According to the consensus of 3 analysts, Inogen has 48.59% upside to fair value with a price target of $10.00 per share.
INGN vs. S&P 500
-
Over the past 5 trading days, Inogen has underperformed the S&P 500 by -8.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Inogen does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Inogen has grown year-over-year revenues for 4 quarters straight. In the most recent quarter Inogen reported revenues of $80.1M.
Earnings Growth
-
Inogen has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Inogen reported earnings per share of -$0.41.
Enterprise value:
64.7M
EV / Invested capital:
--
Price / LTM sales:
0.47x
EV / EBIT:
--
EV / Revenue:
0.19x
PEG ratio (5yr expected):
-0.29x
EV / Free cash flow:
-5.79x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$154.7M
Return On Assets:
-11.55%
Net Income Margin (TTM):
-10.69%
Return On Equity:
-19.02%
Return On Invested Capital:
-19.02%
Operating Margin:
-14.22%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $377.2M | $315.7M | $335.7M | $75.9M | $80.1M | |
| Gross Profit | $153.5M | $126.7M | $154.7M | $28.2M | $36.3M | |
| Operating Income | -$33.1M | -$76.5M | -$42.5M | -$29M | -$11.4M | |
| EBITDA | -$9.6M | -$58.3M | -$21.5M | -$23.8M | -$6.3M | |
| Diluted EPS | -$3.66 | -$4.41 | -$1.52 | -$1.14 | -$0.41 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $305.7M | $329.2M | $304.6M | $207.1M | $185.5M | |
| Total Assets | $461.9M | $489.5M | $405M | $326.2M | $296.2M | |
| Current Liabilities | $56.7M | $61.5M | $65.3M | $72.5M | $76.7M | |
| Total Liabilities | $112.2M | $119.3M | $107.6M | $121.4M | $122.3M | |
| Total Equity | $349.6M | $370.2M | $297.4M | $204.8M | $173.9M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$37.5M | -$3.2M | $5.9M | -$3.1M | -$3M | |
| Cash From Investing | -$10.9M | -$59.3M | -$14M | $4.1M | $11.5M | |
| Cash From Financing | $380K | $960K | $265K | -$14K | -$260K | |
| Free Cash Flow | -$58.8M | -$30.2M | -$11.2M | -$9.5M | -$6.2M | |
INGN
Sector
Market Cap
$178.5M
$34.9M
Price % of 52-Week High
50.49%
42.85%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
0.45%
-40.42%
Beta (5-Year)
1.477
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$7.01
200-day SMA
Sell
Level
$9.57
Bollinger Bands (100)
Sell
Level
7.48 - 10.58
Chaikin Money Flow
Buy
Level
8.4M
20-day SMA
Sell
Level
$7.03
Relative Strength Index (RSI14)
Sell
Level
37.09
ADX Line
Sell
Level
14.73
Williams %R
Neutral
Level
-68.2692
50-day SMA
Sell
Level
$8.09
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Sell
Level
-11.7M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (1.4531)
Buy
CA Score
(Annual)
Level (-0.1594)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (1.6135)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Inogen Inc is a medical technology company that develops and manufactures portable oxygen concentrators used to deliver oxygen therapy to patients with chronic respiratory conditions. Its key product, the Inogen One system, is a lightweight alternative to traditional, stationary oxygen concentrator systems and oxygen tanks. The firm sells its products to home medical equipment providers and also rents products directly to patients. Internationally, It sells its products through distributors large gas companies, and home oxygen providers. It generates the majority of its revenue in the United States.
Stock Forecast FAQ
In the current month, INGN has received 1 Buy ratings 2 Hold ratings, and 0 Sell ratings. The INGN average analyst price target in the past 3 months is $10.00.
-
Where Will Inogen Stock Be In 1 Year?
According to analysts, the consensus estimate is that Inogen share price will rise to $10.00 per share over the next 12 months.
-
What Do Analysts Say About Inogen?
Analysts are divided on their view about Inogen share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Inogen is a Sell and believe this share price will drop from its current level to $10.00.
-
What Is Inogen's Price Target?
The price target for Inogen over the next 1-year time period is forecast to be $10.00 according to 3 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is INGN A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Inogen is a Hold. 2 of 3 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of INGN?
You can purchase shares of Inogen via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Inogen shares.
-
What Is The Inogen Share Price Today?
Inogen was last trading at $6.88 per share. This represents the most recent stock quote for Inogen. Yesterday, Inogen closed at $6.73 per share.
-
How To Buy Inogen Stock Online?
In order to purchase Inogen stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will PayPal Stock Recover or Keep Sliding?
Payments platform behemoth PayPal Holdings, Inc. (NASDAQ:PYPL) is going through…
How High Will Eli Lilly Stock Go By 2030?
The weight loss drugs market is heating up quickly and…
Stock Ideas
Buy
53
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
42
Is NVDA Stock a Buy?
Market Cap: $2.4T
P/E Ratio: 34x
Alerts
Buy
56
ROOT alert for Apr 23
Root [ROOT] is up 9.37% over the past day.
Buy
72
EFX alert for Apr 23
Equifax [EFX] is up 1.69% over the past day.
Buy
51
CALX alert for Apr 23
Calix [CALX] is down 1.81% over the past day.
